In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Hims & Hers Health Inc (NYSE: HIMS) closed the day trading at $32.34 up 2.05% from the previous closing price of $31.69. In other words, the price has increased by $2.05 from its previous closing price. On the day, 25.53 million shares were traded. HIMS stock price reached its highest trading level at $32.7551 during the session, while it also had its lowest trading level at $29.9242.
Ratios:
For a better understanding of HIMS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.69 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 63.42. For the most recent quarter (mrq), Quick Ratio is recorded 1.64 and its Current Ratio is at 1.88. In the meantime, Its Debt-to-Equity ratio is 1.92 whereas as Long-Term Debt/Eq ratio is at 1.92.
Upgrades & Downgrades
In the most recent recommendation for this company, Evercore ISI on January 12, 2026, initiated with a In-line rating and assigned the stock a target price of $33.
On December 09, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $48.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 05 ’26 when Okupe Oluyemi sold 9,070 shares for $33.79 per share. The transaction valued at 306,453 led to the insider holds 91,617 shares of the business.
Okupe Oluyemi sold 23,090 shares of HIMS for $824,710 on Dec 22 ’25. The Chief Financial Officer now owns 94,333 shares after completing the transaction at $35.72 per share. On Dec 22 ’25, another insider, Oluyemi Okupe, who serves as the Officer of the company, bought 32,160 shares for $35.05 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 7362152960 and an Enterprise Value of 7850432000. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 59.79, and their Forward P/E ratio for the next fiscal year is 55.04. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.49. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.33 while its Price-to-Book (P/B) ratio in mrq is 12.66. Its current Enterprise Value per Revenue stands at 3.551 whereas that against EBITDA is 46.705.
Stock Price History:
The Beta on a monthly basis for HIMS is 2.43, which has changed by 0.20908046 over the last 52 weeks, in comparison to a change of 0.19226205 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $23.97. The 50-Day Moving Average of the stock is -13.09%, while the 200-Day Moving Average is calculated to be -29.31%.
Shares Statistics:
Over the past 3-months, HIMS traded about 21.36M shares per day on average, while over the past 10 days, HIMS traded about 13883200 shares per day. A total of 219.12M shares are outstanding, with a floating share count of 206.71M. Insiders hold about 9.20% of the company’s shares, while institutions hold 89.61% stake in the company. Shares short for HIMS as of 1767139200 were 67096243 with a Short Ratio of 3.14, compared to 1764288000 on 67327436. Therefore, it implies a Short% of Shares Outstanding of 67096243 and a Short% of Float of 36.46.
Earnings Estimates
The dynamic stock of Hims & Hers Health Inc (HIMS) is currently attracting attention from 11.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.15, with high estimates of $0.3 and low estimates of $0.1.
Analysts are recommending an EPS of between $0.58 and $0.38 for the fiscal current year, implying an average EPS of $0.48. EPS for the following year is $0.64, with 11.0 analysts recommending between $1.37 and $0.33.
Revenue Estimates
12 analysts predict $617.48M in revenue. The current quarter. It ranges from a high estimate of $624.72M to a low estimate of $608.22M. As of. The current estimate, Hims & Hers Health Inc’s year-ago sales were $481.14MFor the next quarter, 12 analysts are estimating revenue of $655.67M. There is a high estimate of $673.8M for the next quarter, whereas the lowest estimate is $630.7M.
A total of 14 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.35B, while the lowest revenue estimate was $2.33B, resulting in an average revenue estimate of $2.35B. In the same quarter a year ago, actual revenue was $1.48BBased on 13 analysts’ estimates, the company’s revenue will be $2.76B in the next fiscal year. The high estimate is $2.94B and the low estimate is $2.52B.
